Fig. 3
From: Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Mechanism of ICIs-enhanced ACT. ICIs are used to enhance the efficacy of ATC by combining with the corresponding targets to activate T cell anti-tumor immune function and reduce the secretion of inhibitory factors. When CTLA-4 binds to CD80/CD86, the function of TCR-T cells is inhibited. CTLA-4 inhibitors can prevent CTLA-4 from combining with CD80/CD86. The function of TCR-T cells is inhibited when PD1 binds to PD-L1/PD-L2. PD1 inhibitors can prevent PD1 from combining with PD-L1